Acoramidis Alternatives Compared
| Acoramidis | Tafamidis | Vyndaqel (tafamidis) |
|
|---|
| Acoramidis | Tafamidis | Vyndaqel (tafamidis) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis. Acoramidis may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Hereditary Amyloidosis, Transthyretin-Related Amyloidosis. Tafamidis may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vyndaqel may also be used for purposes not listed in this medication guide. |
Related suggestions Cardiomyopathy of Transthyretin-Mediated Amyloidosis
|
|||||||
| More about Acoramidis | More about Tafamidis | More about Vyndaqel (tafamidis) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Tafamidis has an average rating of 7.7 out of 10 from a total of 15 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 0% reported a negative effect. |
Vyndaqel has an average rating of 7.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Acoramidis side effects |
View all Tafamidis side effects |
View all Vyndaqel side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Vyndaqel prices |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
N/A |
|
||||||||
| Brand Names | ||||||||||
| Attruby | Vyndamax, Vyndaqel | Other tafamidis brands include: Vyndamax | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
6 hours |
59 hours |
59 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 23 drugs are known to interact with Acoramidis:
|
A total of 32 drugs are known to interact with Tafamidis:
|
A total of 32 drugs are known to interact with Vyndaqel:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
November 22, 2024 |
May 03, 2019 |
May 03, 2019 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Vutrisiran
Vutrisiran (brand name Amvuttra) is used to treat nerve damage associated with hereditary ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.